DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.400-1.500 for the period, compared to the consensus estimate of 1.420. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the company. Piper Sandler increased their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. Barclays dropped their price objective on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Thursday, June 4th. Finally, Mizuho decreased their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $13.46.
View Our Latest Stock Report on DENTSPLY SIRONA
DENTSPLY SIRONA Stock Down 4.4%
DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts expect that DENTSPLY SIRONA will post 1.42 EPS for the current year.
Insider Activity at DENTSPLY SIRONA
In related news, Director Brian T. Gladden purchased 9,985 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the transaction, the director directly owned 61,849 shares in the company, valued at approximately $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian P. Mckeon acquired 10,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were purchased at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $101,200. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 35,160 shares of company stock valued at $351,179 over the last ninety days. Insiders own 0.46% of the company’s stock.
Institutional Trading of DENTSPLY SIRONA
Several institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC raised its holdings in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC increased its position in DENTSPLY SIRONA by 0.9% in the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after acquiring an additional 92,868 shares during the period. State Street Corp raised its stake in DENTSPLY SIRONA by 5.5% during the 2nd quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier’s stock valued at $113,868,000 after acquiring an additional 369,876 shares during the last quarter. Armistice Capital LLC lifted its position in DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after acquiring an additional 5,234,587 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its position in DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after acquiring an additional 4,003,606 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.
DENTSPLY SIRONA Company Profile
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Featured Stories
- Five stocks we like better than DENTSPLY SIRONA
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
